Aurinia Pharmaceuticals Inc. ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Aurinia Pharmaceuticals Inc. zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Aurinia Pharmaceuticals Inc. zu Deinem Portfolio hinzuzufügen.
Aurinia Pharmaceuticals Inc. reported total revenues of $70M in Q2 '25, aided by record Lupkynis net product sales of $66.6M. AUPH management continues to execute well, maintaining positive cash flow, but faces the risk of having only one revenue-generating drug. AUR200 doesn't appear to be worthless; instead, it could have the potential to compete with other compounds in the same class, althou...
Aurinia Pharmaceuticals (AUPH 2.15%), a biopharmaceutical company focused on therapies for autoimmune diseases, released its second-quarter 2025 earnings on July 31, 2025. The headline news: revenue (GAAP) came in at $70.0 million, which exceeded analyst expectations of $63.8 million by 9.7% (GAAP).
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Gregory F. Keenan - Chief Medical Officer Joseph M.
ROCKVILLE, Md.& EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025.
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025.
I revisit biopharma name Aurinia Pharmaceuticals Inc. for the first time in 2025 after the company reported solid Q1 results in May. The quarter saw Lupkynis net product revenues up 25% year-over-year to $60 million and management reaffirm FY2025 guidance. The company has a strong balance sheet, a free cash flow turnaround, and projected profit growth to $0.59/share in FY2025 to support a posit...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200).
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.